Stockholm Stock Exchange | Mid Cap
3 months
SEBCarnegieHandelsbanken Capital MarketsHandelsbanken

Price Targets For Biogaia

AnalystPrice TargetDateUpside
SEB128 SEKMay 8
Carnegie150 SEKMay 8
Handelsbanken Capital Markets130 SEKFeb -23
Handelsbanken580 SEKSep -21

About The Company

Biogaia AB is a Swedish biotechnology company that develops and sells probiotic products. Biogaia has been developed from research findings on the lactic acid bacterium Limosilactobacillus reuteri and the substance reuterin, which was carried out by Walter Dobrogosz and Sven Lindgren in the 1980s.